Board Meeting Details

The Board of Directors meeting was held on Monday, August 10, 2026. The meeting commenced at 04:00 p.m. and concluded at 04:30 p.m. The board approved and took on record:

1. Unaudited Financial Results for the quarter ended June 30, 2026

2. Limited Review Report from the company's statutory auditors

Financial Results Summary (Standalone)

(All amounts in ₹ lakhs, except EPS)

Income Statement Highlights

  • Total Income: ₹2,080.31 (Q1 FY27) vs ₹2,443.10 (Q1 FY26) vs ₹2,820.67 (Q4 FY26)
  • Other Income: ₹8.06 (Q1 FY27) vs ₹84.69 (Q1 FY26) vs ₹100.69 (Q4 FY26)

Expense Breakdown

  • Cost of materials consumed: ₹1,656.68
  • Change in inventories: (₹533.54) [negative indicates decrease]
  • Employee benefits expenses: ₹296.97
  • Finance costs: ₹83.05
  • Depreciation and amortization: ₹110.74
  • Other expenses: ₹417.43
  • Total Expenses: ₹2,031.33

Profitability Metrics

  • Profit before tax: ₹48.98
  • Tax expense (Deferred Tax): ₹13.40
  • Profit for the period: ₹35.58
  • Total Comprehensive Income: ₹35.58

Earnings Per Share

  • Basic EPS: ₹0.08
  • Diluted EPS: ₹0.08

Comparative Performance

| Particulars | Q1 FY27 (Unaudited) | Q4 FY26 (Audited) | Q1 FY26 (Unaudited) | FY26 (Audited) |

| Total Income | 2,080.31 | 2,820.67 | 2,443.10 | 11,650.55 |

| Profit before tax | 48.98 | 176.44 | 69.14 | 846.01 |

| Profit for period | 35.58 | 35.76 | 60.40 | 741.82 |

| Basic EPS (₹) | 0.08 | 0.14 | 0.13 | 1.64 |

Capital Structure

  • Paid-up equity share capital: ₹473.13 lakhs (Face value of ₹1 per equity share)
  • Number of shares: 47,313,000 (implied from capital and face value)

Segment Information

The company operates within a single primary business segment - 'Pharmaceuticals' - with no other reportable segments as per Ind AS 108.

Audit and Governance

  • The results were reviewed by the Audit Committee and approved by the Board of Directors on August 10, 2026
  • The limited review was conducted by Neeraj Arora & Associates (FRN 021309)
  • The review was performed in accordance with Standard on Review Engagement (SRE) 2410
  • The auditors found no material misstatements and confirmed compliance with Ind AS 34 and SEBI regulations